13 June 2022
Forbes India reported on Bugworks, noting that “[o]ne important aspect of the safety tests in the case of this particular drug is to see if it causes any problems with the heart’s rhythm.” GARDP is providing support for the cardiac safety study (part of the ongoing Phase 1 study).